BOSTON--(BUSINESS WIRE)--Akouos, a precision genetic medicine company developing gene therapies to restore and preserve hearing, today disclosed its lead program, AK-OTOF, a gene therapy focused on ...
- Nonclinical data demonstrate that a single intracochlear administration of an AAVAnc80 vector led to durable restoration of auditory function and was well tolerated, supporting planned clinical ...
BOSTON, April 13, 2021 (GLOBE NEWSWIRE) -- Akouos, Inc. (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback